The US FDA has expanded the approval of Regeneron Pharmaceuticals' fully human monoclonal antibody, Evkeeza (evinacumab-dgnb) ...

Amgen has revealed a significant investment plan, earmarking $650m to enhance its manufacturing operations in the US.

The 100% rate on imported, branded pharma products will not apply to drugmakers constructing manufacturing facilities in the ...

Bucking the trend of IL-12 therapy programme failures, Imunon’s IMNN-001 was bolstered by positive translational data in ...

After demonstrating that its gene therapy can slash Huntington's disease progression by 75%, Uniqure will now file for ...

Evaxion’s preclinical asset targets an unknown infectious disease in which there are no other vaccines available.

Lithuania is rapidly growing as a leading force in the European life sciences scene, with over 400 life sciences companies in ...

Synaffix has entered a licensing agreement with South Korean biopharmaceutical firm Qurient to develop a dual-payload ADC.

Tylenol’s label change plus leucovorin's approval offer a taster to the Trump administration’s plans to crack down on the US ...

Sanofi has committed an additional $625m to its venture capital arm, Sanofi Ventures, bringing its total assets under ...

Vinay Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER), has also been particularly outspoken ...